SCHEMBL5536043

SCHEMBL5536043

CN(C)c1cccc(N[C]=O)c1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 2/20 0.46
SMN1; SMN2 Q16637 2/20 0.46
ALDH1A1 P00352 3/20 0.45
MEN1 O00255 2/20 0.45
KMT2A Q03164 2/20 0.45
TSHR P16473 2/20 0.45
GAA P10253 1/20 0.45
ALOX15 P16050 1/20 0.45
KDM1A O60341 2/20 0.45
MAPK1 P28482 1/20 0.44
BCHE P06276 1/20 0.44
ACHE P22303 1/20 0.44
HIF1A Q16665 1/20 0.40
KCNK3 O14649 2/20 0.39
RCOR1 Q9UKL0 1/20 0.39
NOS1 P29475 1/20 0.38
PNPLA2 Q96AD5 1/20 0.38
HDAC6 Q9UBN7 1/20 0.38
NPC1 O15118 1/20 0.38
LMNA P02545 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL630874 0.80 MEN1 (0.42) MAPTALDH1A1MEN1KMT2AGAA
SCHEMBL3030672 0.79 KDM1A (0.59) MAPTSMN1; SMN2ALDH1A1MEN1KMT2A
SCHEMBL1172183 0.77 CYP1A2 (0.54) MAPTSMN1; SMN2ALDH1A1MEN1KMT2A
SCHEMBL31726567 0.77 ALDH1A1 (0.50) MAPTSMN1; SMN2ALDH1A1MEN1KMT2A
SCHEMBL1268756 0.77 ALDH1A1 (0.50) MAPTSMN1; SMN2ALDH1A1MEN1KMT2A
Hydrochloric Acid SCHEMBL11291701 0.75 ALDH1A1 (0.48) MAPTSMN1; SMN2ALDH1A1MEN1KMT2A
SCHEMBL10089591 0.75 ALDH1A1 (0.48) MAPTSMN1; SMN2ALDH1A1MEN1KMT2A
SCHEMBL11469366 0.75 ALDH1A1 (0.48) MAPTSMN1; SMN2ALDH1A1MEN1KMT2A
SCHEMBL5536053 0.74 ALDH1A1 (0.48) MAPTSMN1; SMN2ALDH1A1MEN1KMT2A
SCHEMBL222552 0.74 ALDH1A1 (0.52) MAPTSMN1; SMN2ALDH1A1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2570418-A2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-03-20 EP disclosed
EP-1555267-B1 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES OTSUKA PHARMA CO LTD (JP) 2013-01-16 EP disclosed
US-7262212-B2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-28 US disclosed
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-05-04 US disclosed
EP-1555267-A1 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-07-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles NR2C2, NR4A3, NR4A2 MAPT 4117/4885SMN1; SMN2 3985/4885ALDH1A1 355/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.